MAXVAX Biotechnology LLC, a Chengdu-based vaccine and novel adjuvant developer, reportedly raised RMB500 million ($73.9 million) in a Series B financing round. The funding was led by China Life Equity Investment and included participation from existing investors Sherpa Healthcare Partners and GL Ventures, as well as new investors Shizhen Capital and Xinshang Capital.
Funding Details
Proceeds from the round will support clinical studies for multiple vaccine pipelines, construction of facilities in Shanghai, and expansion of the company’s talent team.
Pipeline and Future Plans
MAXVAX Bio has a portfolio of preventive and therapeutic vaccines targeting major infectious diseases, including rabies, hepatitis B, allergic diseases, and cancer. The company has over 10 vaccines in development, with two in clinical stages. Additionally, 2-3 vaccines are expected to receive Investigational New Drug (IND) approvals within the next year.-Fineline Info & Tech
